Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Pharmaceutical company developing, manufacturing, and commercializing inhalation products for respiratory diseases; offers CDMO services.
CF PharmTech is a Suzhou, China-based pharmaceutical company that develops, manufactures, and commercializes inhalation products while providing contract development and manufacturing organization services for respiratory disease treatments. The organization produces metered dose inhalers, nasal sprays, nebulizers, and dry powder inhalers for global markets, having secured a total of six product approvals from both the FDA and NMPA. Operating with a workforce of approximately 574 employees, the enterprise generates an estimated $13.4 million in annual revenue through its proprietary product sales and international manufacturing partnerships. The company has raised $205 million in total funding across multiple financing rounds, backed by a syndicate of institutional investors including BioTrack Capital, SDIC Fund, China Capital Investment, and YuanMing Capital. CF PharmTech was founded in 2007 by a group of seasoned pharmaceutical experts and is currently led by Chief Executive Officer Bill Liang.
CF PharmTech has raised $206.0M across 3 funding rounds.
CF PharmTech has raised $206.0M in total across 3 funding rounds.
CF PharmTech has raised $206.0M across 3 funding rounds. Most recently, it raised $51.0M Series F in June 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2020 | $51M Series F | — | Biotrack Capital, CICC Qichen, CICC Qide, GP M&A Fund, Passion Capital, Watson Investment, YuanMing Capital | Announced |
| Jan 2, 2020 | $90M Series E | 蔡磊 | CMB International, CR CP Life Science Fund, Finnova Capital, Gtja Investment Group, Longmen Capital, Oriza Holdings | Announced |
| Aug 28, 2017 | $65M Series D | Sdic Fund | — | Announced |
CF PharmTech has raised $206.0M in total across 3 funding rounds.
CF PharmTech's investors include BioTrack Capital, CICC Qichen, CICC Qide, GP M&A Fund, Passion Capital, Watson Investment, YuanMing Capital, 蔡磊, CMB International, CR-CP Life Science Fund, Finnova Capital, GTJA Investment Group.
CF PharmTech is a fully integrated specialty pharmaceutical company focused on the research, development, manufacturing, and commercialization of inhalation products for respiratory diseases, including allergic rhinitis, asthma, chronic obstructive pulmonary disease (COPD), respiratory infections, pulmonary fibrosis, and pulmonary hypertension.[1][2][3] It serves patients and healthcare providers in the international market by addressing high clinical needs in these areas through innovative drug products, with a pipeline featuring small molecule drugs, siRNA therapies, and candidates like TRN-157 (M3 receptor agonist in Phase 2 for pulmonary emphysema) and CP029 (preclinical for asthma).[2][4]
The company demonstrates growth momentum via an active pipeline with 19 clinical trials, recent initiations (e.g., trials starting in June 2025, October 2024, and September 2024), and a focus on international expansion from its origins in China.[3][4]
CF PharmTech was founded in 2007 in Jiangsu Province, China, evolving from a regional player into a professional pharmaceutical company targeting the international market with integrated R&D, production, and sales capabilities in respiratory diseases.[3] While specific founder details are not publicly detailed in available sources, the company's early emphasis on respiratory therapeutics laid the groundwork for its specialization, leading to pivotal advancements like a diversified pipeline including Phase 2 assets and ongoing clinical trials.[1][4]
CF PharmTech rides the global trend of rising respiratory disease prevalence, driven by aging populations, pollution, and post-pandemic awareness of lung health, where inhalation therapies offer precise delivery for conditions like COPD and asthma.[2] Timing aligns with advances in targeted biologics and small molecules for respiratory unmet needs, bolstered by market forces such as increasing demand for innovative inhalers amid generic competition erosion.[1][4] It influences the ecosystem by contributing to China's biopharma export growth, advancing clinical data that could shape treatment standards, and fostering international partnerships through its pipeline progress.[3][4]
CF PharmTech is poised for expansion with Phase 2 readouts from TRN-157 and preclinical advancements, potentially unlocking partnerships or approvals in major markets.[4] Trends like AI-driven drug discovery, personalized inhalers, and global respiratory health investments will shape its path, amplifying its influence from a China-based innovator to a key respiratory player. This builds on its integrated model, targeting sustained growth in high-need therapeutics.[2][3]